Pearce IP BioBlast™: w/e 09 October 2020

by , | Oct 12, 2020

Significant biosimilar activities this week include

05 Oct 20 | Medicure announced it has entered a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar product for EU, US and Canada. Medicure is responsible for the regulatory approval process for that product.

06 Oct 20 | Onco’Zine reported a new study released by the American Society of Clinical Oncology Quality Care Symposium indicates that Sandoz’s Zarxio® (biosimilar filgrastim) is not only safe and effective, but is cost effective in treating chemotherapy-induced febrile neutropenia in early-stage breast cancer patients.

06 Oct 20 | EU | Samsung Bioepis and Biogen announced the European Medicines Agency has accepted for review its Marketing Authorisation Application for SB11 (proposed ranibizumab biosimilar).

08 Oct 20 | Korea Biomedical Review reported Celltrion has received approval for Ph III trials of CT-P39 (proposed omalizumab biosimilar).

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News